The success of nanoparticle-mediated delivery of antioxidant and antiinflammatory-based neuroprotectants to the brain to improve neuronal functions in neurodegenerative diseases has demonstrated lesser impact instead of achieving its full potential. We hypothesized that these failures were due to a combination of parameters, such as: (i) unavailability of a delivery vehicle, which can reproducibly and efficiently transport through the brain capillary endothelium; (ii) inefficient uptake of therapeutic nanoparticles in the neuronal cell population; and (iii) limited ability of a single nanoparticle to cross the two most-impermeable biological barriers, the blood–brain barrier and mitochondrial double membrane, so that a nanoparticle can travel through the brain endothelial barrier to the mitochondria of target cells where oxidative damage is localized. Herein, we demonstrate optimization of a biodegradable nanoparticle for efficient brain accumulation and protection of astrocytes from oxidative damage and mitochondrial dysfunctions to enhance the neuroprotection ability of astrocytes toward neurons using neurodegeneration characteristics in SOD1G93A rats. This biodegradable nanomedicine platform with the ability to accumulate in the brain has the potential to bring beneficial effects in neurodegenerative diseases by modulating the stars, astrocytes in the brain, to enhance their neuroprotective actions. Significance Neurodegenerative disorders touch many lives in the form of various diseases. Therapeutic interventions of such disorders are limited due to the difficulty in reaching the neurons by crossing the impermeable blood–brain barrier. Scientists have created nanoscopic particles to take therapeutics to the brain; however, the results have not been very encouraging due to the inefficient ability of the nanoplatforms in crossing the blood–brain barrier and to accumulate in the target neuron cells effectively as uptake of nanomaterials by neurons is difficult to achieve. We provide a biodegradable nanoparticle platform with efficient brain astrocyte accumulation properties to provide an alternative approach to tackle neurodegenerative processes by improving and enhancing astrocyte’s natural protection ability toward neurons for neuromedicine.
30 December 2019 in ACS Applied Materials & Interfaces
Oxovanadium(IV) complexes [VO(aip)(L)](ClO4)2 (L = phtpy, 1; stpy, 2) and [VO(pyip)(L)](ClO4)2 (L = phtpy, 3; stpy, 4), where aip is 2-(9-anthryl)-1H-imidazo[4,5-f][1,10]phenanthroline, pyip is [2-(1-pyrenyl)-1H-imidazo[4,5-f][1,10]phenanthroline, phtpy is (4′-phenyl)-2,2′:6′,2′′-terpyridine and stpy is (2,2′:6′,2′′-terpyridin-4′-oxy)ethyl-β-D-glucopyranoside, were prepared, characterized and their DNA binding and photocleavage activity, cellular uptake and photocytotoxicity in visible light were studied. The complexes are avid binders to calf thymus DNA (Kb ∼105 mol−1). They efficiently cleave pUC19 DNA in red light of 705 nm via the formation of HO˙ species. The glucose appended complexes 2 and 4 showed higher photocytotoxicity in HeLa and Hep G2 cells over the normal HEK 293T cells. No such preference was observed for the phtpy complexes 1 and 3. No significant difference in IC50 values was observed for the HEK 293T cells. Cell cycle analysis showed that the glucose appended complexes 2 and 4 are more photocytotoxic in cancer cells than in normal cells. Fluorescence microscopy was done to study the cellular localization of complex 4 having a pendant pyrenyl group.
We report the synthesis of a curcumin–cisplatin combination chemotherapeutic agent, Platin-C, suitably packaged in a mitochondrion-targeted nanovehicle for enhanced anticancer efficacy and diminished chemotherapy-associated inflammation.
Herein, we synthesized CuPer-BSA-NPs that release Cu2+ and H2O2 at acidic pH, activating a Fenton-type reaction to produce ˙OH radicals, which polarize RAW 264.7 macrophages to the M1 phenotype for enhanced anti-cancer effects against HeLa cells.